



Updated: 20 February, 2025  
for the latest programme update,  
please download agenda on  
conference website

5<sup>th</sup> Edition

# The Global Project Management, Portfolio Planning and Partnerships for Generics & Biosimilars

- Global PPM conference focused on Generics




Toronto | Canada (in-person event)



September 24 - 25 , 2025

# 2025 PPM Summits Worldwide



World's Greatest PHARMA,  
BIOTECH & HEALTHCARE  
Project and Portfolio  
Management Conferences  
UNITED under WHY Summits  
PPM WORLD TOUR

*"ALWAYS BE CURIOUS"*

[WWW.WHYSUMMITS.COM](http://WWW.WHYSUMMITS.COM)

# Conference Themes



## Wednesday

September 24, 2025

Global vs. Emerging Market Opportunities

PM's role in Product Development

Going on Market – What to be Focused on?

Risk Management

## Thursday

September 25, 2025

Business Development and Outsourcing

Strategic Partnerships for Economic Growth

Stakeholder Management Skills

Artificial Intelligence in Generic Formulation Projects  
– The Future of Pharma



# Reasons to attend



Friendly and highly stimulating atmosphere in a smaller circle (around 150 attendees per conference)



Fun icebreaking social events every evening with delegates, speakers and sponsors of the event



Creative and inspiring platform for fruitful discussion




Workshops and Roundtables for a deeper dive into important topics in the Pharma industry now



Sharing new ideas and building strong connections



Big & SME Pharma and Biotech companies



## Testimonials



"An event where everyone could participate in the conversation. Great mix of Panel discussion, round table and presentations that give the ability to network and meet everyone in the room."



**Kelly Keen**

Global Project & Portfolio Manager

# Testimonials



**Blerim Shkodra**  
Sr Director Capital Procurement &  
Category Leader  
Lonza



It was a real pleasure being part of this great event.



**David Swift**  
Senior Procurement Leader  
Lonza



Great discussions and insights from some of the best in the business



**Mugunthan Maheswaran**  
Sr Project Manager, Technology,  
Digital & Operational Excellence  
Roche



It was a very transparent discussion on Agile, waterfall and hybrid methodologies. I have fully enjoyed participating in this panel!



**Christophe De Vleeschouwer**  
Director, Pipeline Project  
Management  
GSK Vaccines



Very good and engaging discussion! Thanks Why Summits for being part of the panel



**Bhaskar V. Sathaye**  
Lead Project Engineer  
The Janssen Pharmaceutical  
Companies of Johnson & Johnson



A big bravo to the Why Summit Team for organizing the great conference. Excellent speakers, fantastic attendee!



**Noel Decker**  
VP and Head, Science & Development  
Project Management, Strategy and  
Business Operations  
Emergent BioSolutions



Reflecting on my participation in the 22<sup>nd</sup> American Pharma and Biotech Project, Program, and Portfolio Management Conference in San Francisco last week, I am inspired by the wealth of knowledge shared and the incredible community of experts and lifelong learners I had the pleasure of working with and connecting to.



**Zane Zaleska**  
Senior Project Manager



The Why Summit conference touched not only my mind, but also my heart. So many presenters emphasized the people skills and common sense in PPM which aligns with my personal values. At the core of every project are people and their wellbeing



**Raffaele Marranzini**  
CEO  
Platflow



Thank you for giving me the opportunity to speak in front of this specialized PPM audience within the broader context of PLM.



**Peter C. Luke**  
Project Corporate Vice President - API  
Expansion  
Novo Nordisk



Thanks for the opportunity to share lessons learned at the conference. Also, very well planned and managed event with great speakers and highly relevant network. Big thanks to Radoslava Gregová and Tomas Rendek for their very professional support.



**Emmanuel Happe**  
Senior Leader | Global Director



Thanks to Why Summits and the Great Speakers and Panels. Very inspiring. So many great things to do to provide a better Life for our patients



**Dhawal Upadhyay**  
General Manager - Global Program  
Management  
Intas Pharmaceuticals  
(Biopharma division)



It was an honor to be part of such a prestigious event and to contribute to discussions. Thanks Why Summits for the opportunity to engage with such a knowledgeable audience and networking with industry leaders !!



**Dave Penndorf**  
PPM Advisor  
Groundswell Pharma Consulting,  
LLC.



Always a fun time MCing the Why Summits conferences! It's the intersection of a topic I'm so deeply passionate about (PPM), the industry I know so much about (life science in general, pharma in particular), and the people who - dare I say it - have become my friends.

# Industry Pioneers Attending From



# Dear Colleague,



Navigating the complex world of generics & biosimilars requires exceptional portfolio prioritization, agile capacity management, resource allocation, and business development. To help you excel in this ever-changing landscape, we're excited to present a 2-day conference packed with in-depth content, interactive discussions, and valuable networking opportunities at the annual Global Project Management, Portfolio Planning and Partnerships for Generics Conference.

Join us in Toronto, where industry leaders and fellow executives will come together at the nexus of science, business, and operations to advance Generic Formulation Projects, Business Development, and Strategic Partnerships. By attending, you'll gain cutting-edge tools, insights, and organizational strategies to enhance your strategic decision-making, optimize portfolio prioritization and resource planning, and foster value and resilience in your organization.

Here's what you can expect at the conference:

- Engage in dynamic, interactive discussions with industry experts and peers.
- Discover innovative solutions and strategies to tackle today's strategic partnership challenges.
- Build lasting connections with fellow executives and thought leaders in the field.
- Gain access to exclusive insights, tools, and best practices to optimize your decision-making process.
- Don't miss this unique opportunity to elevate your stakeholder management skills and network with key decision-makers.

Mark your calendar and join us for this game-changing event that will redefine your approach to project, program, and portfolio management in the generics industry.

We look forward to seeing you in Toronto!  
Best regards,

A handwritten signature in blue ink that reads "Andrea Beneová". The signature is stylized and fluid, with a long horizontal line extending from the end.

**Andrea Beneová**  
Event Producer

# Speakers & Panelists



**sanofi**

**Adeline Luciano**

Site Project Leadership, Toronto  
Manufacturing & Supply  
Sanofi



**SANDOZ**

**Christian Ouellet**

Vice-President – Corporate Affairs  
Sandoz



**Dhairya Maheshwari**

Business Head Canada  
Intas B2B



**Dominic Ferris**

Senior Director  
Apotex Inc



**STERIMAX INC.**

**Edward Morrison**

Executive Vice President  
SteriMax Inc.



**Genia Radeva**

VP Market Access & Technical Operations  
Jamp Pharma Group



**Jon Green**

Director of Regulatory Affairs  
Compliance and Licensing  
Mallinckrodt Pharmaceuticals



**Kristin Willemsen**

Vice President, Scientific & Regulatory  
Affairs  
Canadian Generic Pharmaceutical  
Association



**Dr. Marielouise Abi Hanna**

Corporate Strategy & Market Access  
Creaiviti



**STERIMAX INC.**

**Mark Lobe**

Chief Operating Officer  
SteriMax Inc.



# Speakers & Panelists



**Olenka Crewe**

Vice President BD & Business  
Development & Scientific Affairs  
Mint Pharmaceuticals



**Omar Jabri**

Head of Intellectual Property  
Argentum Pharmaceuticals LLC



**Paul Varady**

Vice President – Quality and Regulatory  
Affairs  
Juno Pharmaceuticals



**Rana Harb**

Vice President – Regulatory Affairs,  
Compliance, Quality Assurance,  
Pharmacovigilance  
Aurobindo



**Rosemarie Childerhose**

Head, Market Access & Pricing  
Biocon Biologics



**Sandeep Kumar**

Director – Product Development, R&D



**Sandra Tomassini**

Vice President, Alliance Management  
Apotex Inc



**Sanyukta Kher**

Senior Director, Head of Regulatory  
Affairs  
Mint Pharmaceuticals

# Agenda

## Day1

### GLOBAL VS EMERGING MARKET OPPORTUNITIES

**8:30 CASE STUDY: NAVIGATING THROUGH MARKET DYNAMICS: PRICING, COMPETITION, AND API INTEGRATION**

In this case study, we delve into the intricacies of market analysis, focusing on essential details that businesses must consider to stay competitive and thrive. From pricing strategies to understanding generic competition and the integration of API companies, we explore key factors that shape market dynamics and influence strategic decision-making.

**Rosemarie Childerhose**, Head, Market Access & Pricing, **Biocon Biologics**

**9:00 RESERVED PRESENTATION: ENHANCING SALES EFFECTIVENESS FOR PHARMA GENERICS IN DIVERSE MARKETS**

Investigate the key factors that drive sales effectiveness for generic pharmaceuticals in both global and emerging markets. Discuss tailored sales strategies, understanding market-specific customer needs, and leveraging local insights to optimize sales performance.

**9:30 KEYNOTE: UNLOCKING OPPORTUNITIES: EXPANDING CANADIAN GENERICS INTO EMERGING MARKETS**

This keynote will explore the strategic pathways for Canadian generic pharmaceutical companies to successfully enter and thrive in emerging markets. From navigating regulatory landscapes to building partnerships and optimizing supply chains, the session will provide actionable insights and best practices to leverage the growing demand for high-quality, affordable medicines in these regions. Attendees will gain a comprehensive understanding of market dynamics and how to position Canadian generics for sustainable growth.

**Dr. Marielouise Abi Hanna**, Corporate Strategy & Market Access, **Creaviti**

**10:00 PANEL DISCUSSION: STRATEGIES FOR MARKET ENTRY – CANADIAN GENERICS**

This keynote covers critical considerations such as regulatory requirements, market approval timelines, and mitigating country-specific risks. Learn effective modes of entry including joint ventures, subsidiaries, and licensing agreements, alongside tailored go-to-market strategies for B2B, B2C, and hybrid models.

**Dr. Marielouise Abi Hanna**, Corporate Strategy & Market Access, **Creaviti**  
**Paul Varady**, Vice President – Quality and Regulatory Affairs, **Juno Pharmaceuticals**

**10:30 NETWORKING BREAK**



17:30

### NIGHT BEFORE THE EVENT - MEET & GREET

Welcome to our event! We are so honored and grateful to have you with us!

Come and join us for some drinks, where you will be able to do an early bird registration along with some firsthand networking! All the delegates will start arriving and we will all have a chance to get to know one another - the sooner the better. Drinks, conversations, handshakes, smiles, hugs, whether with your old or new friends from the industry - everyone is welcome!

### PM's ROLE IN PRODUCT DEVELOPMENT

**11:00 PANEL DISCUSSION: OPPORTUNITIES AND CHALLENGES FOR DIFFERENT GENERIC DRUG TYPES**

What Project and Portfolio Managers need to do to succeed in markets of different Generic drug types. We discuss the opportunities these markets are providing, what are the major challenges, and how to tackle them.

- Oral Solids
- Biosimilars
- Respiratory Products
- Sterile Injectables
- OTC

**Sandra Tomassini**, Vice President, Alliance Management, **Apotex Inc**

**Rana Harb**, Vice President – Regulatory Affairs, Compliance, Quality Assurance, Pharmacovigilance, **Aurobindo**

**Rosemarie Childerhose**, Head, Market Access & Pricing, **Biocon Biologics**

**Sandeep Kumar**, Director – Product Development, R&D

**Sanyukta Kher**, Senior Director, Head of Regulatory Affairs, **Mint Pharmaceuticals**

**11:30 RESERVED PRESENTATION: A STRUCTURED & DISCIPLINED APPROACH TO PRODUCT DEVELOPMENT**

Discover how structured and disciplined approach to product development can streamline your journey from concept to market. We'll discuss innovative methodologies and tools that ensure efficient project management, regulatory compliance, and market readiness. Learn how solutions can empower pharmaceutical generics companies to accelerate timelines, reduce costs, and enhance product quality, ultimately driving competitive advantage in the industry.

# Day1

## GOING ON MARKET – WHAT TO BE FOCUSED ON?

- 12:00 **KEYNOTE:** GENERIC PRODUCT LAUNCH – HOW TO STAY PATIENT-CENTRIC?  
Development and launch of generic and biosimilar products play a crucial role in expanding access to affordable healthcare options. This keynote will focus on embracing patient-centricity in product development and launch, ensuring that the needs and preferences of patients are at the forefront and discuss post-launch strategies, including lifecycle management, pharmacovigilance, and market share optimization.  
**Dominic Ferris**, Senior Director, **Apotex Inc**
- 12:30 LUNCH BREAK
- 13:30 **KEYNOTE:** NAVIGATING THE REGULATORY AND COMPLIANCE CHALLENGES FOR BIOSIMILARS IN CANADA AND OTHER MAJOR MARKETS  
• Alignments and misalignments of regulatory requirements for Biosimilars between Canada, Europe and US regulatory agencies  
• Complexity of Biosimilars versus chemical drugs and how to navigate these complexities  
• GMP Mutual Recognition Agreements between Health Canada and other agencies : Pros and Cons  
**Rana Harb**, Vice president, **Aurobindo**
- 14:00 **RESERVED PRESENTATION:** ALIGNING R&D EFFORTS WITH SALES EFFECTIVENESS IN PHARMA GENERICS  
Explore strategies to integrate R&D activities with sales effectiveness initiatives in the generics market. Discuss how early collaboration between R&D and sales teams can optimize product development timelines, enhance market adoption, and improve commercial success.
- 14:30 **PANEL DISCUSSION:** REGULATORY CHALLENGES OF COMPLEX GENERICS AND COMBINATION PRODUCTS AND HOW TO DEAL WITH THEM  
• What specific regulatory challenges do complex generics and combination products face in Canada and other international markets?  
• How do Canadian regulatory requirements for complex generics differ from those in the US and Europe?  
• What are the disparities among regulatory agencies worldwide and how can companies effectively navigate these differences?  
• Based on industry experience, what are the best practices for submitting ANDS applications in Canada without product-specific guidance?  
**Jon Green**, Director of Regulatory Affairs Compliance and Licensing, **Mallinckrodt Pharmaceuticals**  
**Kristin Willemssen**, Vice President, Scientific & Regulatory Affairs, **Canadian Generic Pharmaceutical Association**  
**Sanyukta Kher**, Senior Director, Head of Regulatory Affairs, **Mint Pharmaceuticals**
- 15:00 NETWORKING BREAK
- 15:30 **ROUNDTABLE DISCUSSIONS**

## RISK MANAGEMENT

- 16:00 **WORKSHOP:** TYPES OF RISK IN GENERIC FORMULATION PROJECTS (60MIN)  
Delve into the multifaceted landscape of risks inherent in generic pharmaceutical formulation endeavors. Gain insights into identifying, assessing, and mitigating challenges related to formulation, regulatory compliance, supply chain, market dynamics, and more.  
**Olenka Crewe**, Vice President BD & Business Development & Scientific Affairs, **Mint Pharmaceuticals**
- 17:30 **THAT'S A WRAP!**  
But we still have something special and exciting planned! No need to rush to the train station or the airport, we still have some fun things planned for you!

# Day1

## Day 1 Roundtable Discussions

### 1) GENERIC COMPETITION IN CANADA: STRATEGIES FOR ECONOMIC SUSTAINABILITY

**Christian Ouellet**, Vice-President – Corporate Affairs, **Sandoz**

### 2) PM'S ROLE IN PRODUCT DEVELOPMENT

**Olenka Crewe**, Vice President BD & Business Development & Scientific Affairs, **Mint Pharmaceuticals**

**Paul Varady**, Vice President – Quality and Regulatory Affairs, **Juno Pharmaceuticals**

### 3) BIOSIMILARS – OPPORTUNITIES, CHALLENGES, AND OUTLOOK

**Rosemarie Childerhose**, Head, Market Access & Pricing, **Biocon Biologics**

**Rana Harb**, Vice President – Regulatory Affairs, Compliance, Quality Assurance, Pharmacovigilance, **Aurobindo**

### 4) REGULATORY CHALLENGES WITH FOCUS ON EMERGING MARKETS

**Sandeep Kumar**, Director – Product Development, **R&D**

**Sanyukta Kher**, Senior Director, Head of Regulatory Affairs, **Mint Pharmaceuticals**

### 5) EMERGING MARKETS – WHERE ARE THE OPPORTUNITIES

**Dr. Marielouise Abi Hanna**, Corporate Strategy & Market Access, **Creaiviti**

### 6) FROM PRODUCT LAUNCH TO U.S. DISTRIBUTION: PRACTICAL PHARMA STRATEGIES

**Jon Green**, Director of Regulatory Affairs Compliance and Licensing, **Mallinckrodt Pharmaceuticals**



# Day2

## BUSINESS DEVELOPMENT AND OUTSOURCING

### 8:30 **CASE STUDY: CRAFTING EFFECTIVE PATENT LITIGATION STRATEGIES FOR GENERICS AND BIOSIMILARS**

Uncover the intricate web of patent litigation within the realm of generics and biosimilars through this case study. Gain a comprehensive understanding of navigating complex legal procedures and discover techniques to effectively address challenges. Discover the power of crafting innovative intellectual property strategies to unlock market potential and thrive in the fiercely competitive arena of generics and biosimilars.

**Omar Jabri**, Head of Intellectual Property, **Argentum Pharmaceuticals LLC**

### 9:00 **PANEL DISCUSSION: HOW TO UTILIZE BD FOR SUCCESSFUL PARTNERSHIPS – TIPS & TRICKS**

Gain valuable insights from a real-world examples that delve into the journey of a generics company in establishing and maintaining successful partnerships. Uncover the critical role of Business Development in identifying, evaluating, and structuring partnerships. Learn how to align BD strategies with PPM objectives to identify the right partners and opportunities.

**Dhairya Maheshwari**, Business Head Canada, **Intas B2B**

**Olenka Crewe**, Vice President BD & Business Development & Scientific Affairs, **Mint Pharmaceuticals**

**Sandra Tomassini**, Vice President, Alliance Management, **Apotex Inc**

**Sandeep Kumar**, Director – Product Development, R&D

### 9:30 **RESERVED PRESENTATION: LEVERAGING BUSINESS INTELLIGENCE FOR PREDICTIVE INNOVATION VALUATION**

Explore how cutting-edge business intelligence solutions empower organizations to accurately predict the value of innovative products, enabling informed decision-making and strategic investments in product development and market expansion.

### 10:00 **NETWORKING BREAK**

## STRATEGIC PARTNERSHIPS FOR ECONOMIC GROWTH

### 10:30 **PANEL DISCUSSION: POWER OF OUTSOURCING**

Examine the advantages and drawbacks of outsourcing and insourcing strategies in the context of generic and biosimilar development. Discuss decision criteria to determine when to outsource specific project components and when to keep processes in-house. Discuss key considerations for selecting the right partners, negotiation tactics, and building mutually beneficial relationships. Explore how external expertise, specialized equipment, and advanced technologies from CROs can drive breakthroughs in research, development, and manufacturing.

**Paul Varady**, Vice President – Quality and Regulatory Affairs, **Juno Pharmaceuticals**

11:00

### **RESEVED PRESENTATION: WHY PARTNERING SOLUTIONS HELP YOUR BUSINESS GROW**

Explore the strategic advantages of partnering solutions in driving growth within the pharmaceutical generics sector. This presentation will delve into the benefits of strategic alliances, collaborations, and licensing agreements in expanding market reach, accessing new technologies, and optimizing operational efficiencies. Learn how effective partnering can enhance innovation capabilities and accelerate business development initiatives for sustainable growth and competitive advantage.

## STAKEHOLDER MANAGEMENT SKILLS

11:30

### **KEYNOTE: RESOURCE MANAGEMENT - MATCHING PEOPLE & PRIORITIES**

PMO organizations embracing resource management effectively maintain their competitive edge in times of resource constraints, skills scarcity, flat budgets, and ambitious R&D agendas. With the most efficient resource utilization at the top of the list, these organizations significantly reduce the overall project cycle time and maximize their portfolio's throughput. We will also include here a debate and real examples of how one company's PMO leveraged the PMO people, processes, tools and templates to deploy a practical, scalable and sustainable resource management solution.

**Adeline Luciano**, Site Project Leadership, Toronto Manufacturing & Supply, **Sanofi**

12:00

### **LUNCH BREAK**

13:00

### **KEYNOTE: EXPLORING THE ESSENTIAL SOFT SKILLS FOR EFFECTIVE STAKEHOLDER MANAGEMENT IN PPM**

Unlocking Stakeholder Success: Essential Soft Skills for Effective Management. Explore the critical soft skills required to navigate and influence stakeholder dynamics. Learn how to master communication, emotional intelligence, conflict resolution, and relationship-building techniques. Acquire the tools to cultivate lasting partnerships, mitigate challenges, and steer projects towards success by harnessing the power of interpersonal skills.

**Christian Ouellet**, Vice-President – Corporate Affairs, **Sandoz**

13:30

### **PANEL DISCUSSION: BUILDING TOP NOTCH ALLIANCE NETWORKS**

Discover cutting-edge strategies to forge and manage strategic alliances, fostering collaborations that accelerate innovation, enhance production capabilities, and streamline distribution networks. Uncover insights on effective partner selection, negotiation tactics, and maintaining sustainable partnerships. Elevate your alliance-building prowess and exchange industry best practices.

**Edward Morrison**, Executive Vice President, **SteriMax Inc.**

**Dr. Marielouise Abi Hanna**, Corporate Strategy & Market Access, **Creaiviti**

# Day2

- 14:00 **KEYNOTE + WORKSHOP: MASTER YOUR LEADERSHIP POTENTIAL (60MIN)**  
This engaging workshop will equip you with the key leadership skills to thrive in the dynamic pharmaceutical industry.
- Empowering Session: Dive into an interactive workshop designed to ignite your leadership journey.
  - Collaborative Activities: Work in teams to hone your communication and problem-solving skills through engaging exercises.
  - Unlock Your Leadership: Discover your unique leadership style through self-assessments and interactive discussions
- Genia Radeva**, VP Market Access & Technical Operations, **Jamp Pharma Group**
- 

15:00 NETWORKING BREAK

15:30 **AFTERNOON ASK'N'LEARN ROUNDTABLE DISCUSSIONS**

---

## ARTIFICIAL INTELLIGENCE IN GENERIC FORMULATION PROJECTS – THE FUTURE OF PHARMA

16:00 **WORKSHOP: AI IN HEALTHCARE (60MIN)**

### 1) TIMELINE OF AI IN HEALTHCARE

### 2) RECENT AI TECHNOLOGY ADVANCEMENT THAT BREAKS ENTRY BARRIER

### 3) AI PLATFORMS – USE, DON'T BUILD (WITH EXAMPLES)

### 4) USE CASES FOR EHR DATA, DRUG DISCOVERY, DIAGNOSIS AND PERSONALIZED MEDICINE

---

17:00 THAT'S A WRAP!

# Day2

---

## Day 2 Roundtable Discussions

### 1) TO OUTSOURCE OR NOT TO OUTSOURCE

**Paul Varady**, Vice President – Quality and Regulatory Affairs, **Juno Pharmaceuticals**

### 2) IP STRATEGIES FOR GENERICS AND BIOSIMILARS

**Omar Jabri**, Head of Intellectual Property, **Argentum Pharmaceuticals**

### 3) BEHAVIOR OF INTERNAL STAKEHOLDERS IN PROJECT & PORTFOLIO MANAGEMENT AND ITS IMPACT ON SUCCESS

### 4) BUSINESS DEVELOPMENT SKILLS

**Olenka Crewe**, Vice President BD & Business Development & Scientific Affairs, **Mint Pharmaceuticals**

**Dhairya Maheshwari**, Business Head Canada, **Intas B2B**

### 5.) RESOURCE MANAGEMENT IN SMALL VS BIG PHARMA

**Adeline Luciano**, Site Project Leadership, Toronto Manufacturing & Supply, **Sanofi**

### 6) AI IN HEALTHCARE

### 7) HOW TO DRIVE ORGANIZATIONAL ALIGNMENT

**Dr. Marielouise Abi Hanna**, Corporate Strategy & Market Access, **Creaiviti**

**Mark Lobe**, Chief Operating Officer, **SteriMax Inc.**

# 2025 PPM Summits Worldwide



- 1** 22 - 23 January, BARCELONA  
28<sup>th</sup> European Pharma and Biotech Project, Program and Portfolio Management Conference
- 2** 22 - 23 January, BARCELONA  
3<sup>rd</sup> Global Project Management, Portfolio Planning And Partnerships For Generics & Biosimilars
- 3** 29 - 30 January, SAN DIEGO  
American Strategic Portfolio Management in Life Sciences – West Coast
- 4** 3 - 4 April, BASEL  
29<sup>th</sup> European Biopharma Project Program and Portfolio Management Conference
- 5** 9 - 10 April, CHICAGO  
2<sup>nd</sup> American Medical Device Project & Portfolio Management Conference
- 6** 15 - 16 April, PHILADELPHIA  
24<sup>th</sup> American Pharma and Biotech Project, Program and Portfolio Management Conference
- 7** 14 - 15 May, LONDON  
European Strategic Portfolio Management in Life Sciences
- 8** 3 - 4 June, COPENHAGEN  
Biopharma PPM in Clinical Research and Development Summit Edition
- 9** 11 - 12 June, BERLIN  
2<sup>nd</sup> European MedTech Summit 2025 - Medical Device Project & Portfolio Management Conference
- 10** 11 - 12 June, SAN FRANCISCO  
25<sup>th</sup> American Pharma and Biotech Project, Program and Portfolio Management Conference
- 11** 5 - 6 August, SINGAPORE  
Asian Pharma and Biotech Project, Program and Portfolio Management Conference
- 12** 3 - 4 September, MELBOURNE  
Pharma and Biotech Project, Program and Portfolio Management Conference
- 13** 10 - 11 September, MUMBAI  
3<sup>rd</sup> Strategic Project, Program and Portfolio Management Conference for Pharmaceuticals
- 14** 24 - 25 September, TORONTO  
5<sup>th</sup> Global Project Management, Portfolio Planning and Partnerships for Generics & Biosimilars
- 15** 8 - 9 October, BASEL  
30<sup>th</sup> European Pharma and Biotech Project, Program and Portfolio Management Conference
- 16** 15 - 17 October, BOSTON  
26<sup>th</sup> American Pharma and Biotech Project, Program and Portfolio Management Conference
- 17** 22 - 23 October, LONDON  
31<sup>st</sup> European Pharma and Biotech Project, Program and Portfolio Management Conference
- 18** 9 - 11 December, LAS VEGAS  
2<sup>nd</sup> Annual PPM TOOLBOX SUMMIT



# Our Partners



# Sponsorship



Additional sponsorship opportunities are available for those who wish to further customize their involvement.

## Exhibiting

With a large and senior audience and decision makers, thoroughly selected, exhibiting at any Summit at 2024 PPM SUMMIT WORLD is a popular sponsorship option with great value for solution providers.

Sponsorship includes:

- Selected Summit Three Access Passes
- Exhibition space
- Helping to prearrange face to face meetings with selected participants

## Dinner Sponsorship

2024 PPM SUMMIT WORLD TOUR will host a series of dinners. These dinners bring together thoughtfully selected groups of 15-20 peers from established pharma, biotech, healthcare, and medtech companies. The dines start with a 30 minute networking reception followed by a 60 minute seated dinner, with the option for participants to remain afterward to continue networking.

- Selected Summit Three Access Passes
- 30-minute reception, and 60 minute seated dinner

## Speaking

Limited speaking opportunities are available for our sponsoring partners to demonstrate the expertise of their organization. Be sure to ask about these early so we can ensure your presentation flows seamlessly with the overall content. Speaking sponsorships has several options – keynote presentations, case study presentations, expert presentations, panel discussions, workshops or roundtable leadership. Speaking opportunities are available for experts in the field of Project and Portfolio Management, Contract Management, Consultancy, CMO, CRO, Data Management and Intelligence, Artificial Intelligence, Robotics, IoT and Digital Innovations.

# Contact us

Updated: 20 February, 2025  
for the latest programme update, please  
download agenda on conference website



## SPEAKING:

**Andrea Beneová**

[andrea.b@whysummits.com](mailto:andrea.b@whysummits.com)



## ATTENDING AND SPONSORING:

**Srihari Kamban**

[shk@whysummits.com](mailto:shk@whysummits.com)

REGISTER HERE



FROM  
**2699CAD**

## DISCLAIMER

Please note – all of the information in this document is subject to change at any time. Whilst every effort has been made to ensure the accuracy of the information, statements and decisions recorded in them, their status will remain that of a draft until such time as they are confirmed as a final version prior the subsequent meeting. Additionally, the user information is only valid at a certain moment in time and is subject to change due to movement and changes in bit rate requirements.